Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.

Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.

Abstract: Provided herein, in some embodiments, are antibodies, antigen-binding antibody fragments, chimeric antigen receptors (CARs) and bispecific T cell engagers (BiTEs) that bind specifically to B7 homolog 6. Also provided herein are methods of using the same and cells comprising the same.

Abstract: The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell.

Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.

Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.

Abstract: A method of modulating immunity in a mammal is provided by modulating Galectin-9 activity in the mammal. Promoting or enhancing immunity may be effected by activating or stimulating Galectin-9 activity in the mammal, such as by administering a Galectin-9 agonist to the mammal. The agonist may be multimeric, soluble PD-L2 or an agonist antibody that binds Galectin-9. Suppressing or preventing immunity may be achieved by inhibiting or blocking Galectin-9 activity in the mammal, such as by administering an antagonist antibody or antibody fragment that binds Galectin-9 or that prevents or inhibits PD-L2 multimerisation and/or binding to Galectin-9. The aforementioned methods may be suitable for preventing or treating a disease, disorder or condition responsive to modulation of Galectin-9 activity. Also provided is a method of designing, screening, engineering or otherwise producing a Galectin-9 agonist, inhibitor or antagonist that may be useful for modulating immunity by modulating Galectin-9 activity.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: Provided are novel anti-TNFRSF21 antibodies and antibody drug conjugates, and methods of using such anti-TNFRSF21 antibodies and antibody drug conjugates to treat cancer.

Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.

Abstract: The present invention relates to biotechnology and comprises isolated monoclonal antibodies, in particular human monoclonal antibodies, which specifically bind to PD-1 with high affinity. The antibodies according to the invention may be chimeric, humanized or human antibodies, or antigen-binding fragments thereof, and may be used as a medicinal agent in oncology and immuno-oncology, for treating diseases associated with various cell proliferation or development disorders. The invention also relates to methods for producing said antibodies and a method for treating human diseases using said antibodies.

Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

Abstract: The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA.

Abstract: The invention relates to a bispecific HER2-targeting agent that includes (a) a first polypeptide ligand that binds to HER2 extracellular domain 1, (b) a second polypeptide ligand that binds to HER2 extracellular domain 4, and (c) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand.

Abstract: The present invention concerns methods for identifying, producing, and engineering binding molecule conjugates, and to the conjugates produced. In particular, the invention concerns Surrobody conjugates composed of an antibody heavy chain variable domain and a surrogate light chain, wherein the surrogate light chain and/or the antibody heavy chain variable domain is conjugated to a therapeutic or diagnostic agent.

Abstract: Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.

Abstract: In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation.

Abstract: Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.

Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an l=g light chain (or functional fragment thereof).

Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.

Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.

Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.

Abstract: Provided are compositions and methods of making hydrogels, aerogels, films and composites directly from a microbial culture or complex mixture using curli nanofibers.

Abstract: Disclosed is a dispersion of metal-containing oxidized cellulose nanofibers with superior dispersibility, which is applicable to various uses. The disclosed metal-containing oxidized cellulose nanofiber dispersion comprises a dispersion medium, and metal-containing oxidized cellulose nanofibers containing a metal other than sodium in salt form, wherein the metal-containing oxidized cellulose nanofibers have a number-average fiber diameter of 100 nm or less and an average degree of polymerization of 100 to 2,000.

Abstract: The present disclosure is generally directed to biopolymers having coiled nanostructures, methods of making those biopolymers, and applications involving those biopolymers. Biopolymers having coiled nanostructures may be produced through a biophysical process by which the shape of a biopolymer macromolecular chain is altered. Biopolymers having coiled nanostructures may then be cross-linked to prepare biopolymeric networks. The biopolymeric networks may be configured to incorporate solid particles, in which they serve to hold the solid particles together against external stresses, solvents, and the like. For this reason, the biopolymers having coned nanostructures are useful in a variety of applications, including in an improved process for forming iron ore pellets.

Abstract: The present invention provides a method for extracting Tremella polysaccharides by using buffer solution, which comprises the following steps: leaching Tremella powder in a buffer solution with heating to obtain the leachate; subjecting the said leachate to solid-liquid separation and obtaining the liquid component which contains Tremella polysaccharides; subjecting the said liquid component to alcohol precipitation, and the precipitate obtained is Tremella polysaccharides. According to the method of the invention, various buffer solutions can achieve the extraction rates of Tremella polysaccharides up to 33:12%, which is 3 to 4 times of that of the traditional water extraction method, and greatly improve the extraction yields of Tremella polysaccharides.

Abstract: The invention relates to a method for obtaining beta glucan from yeast cells, at least comprising the following steps: A. enriching yeast cells (10); B. forming a yeast suspension comprising at least constituents of the yeast cells enriched in accordance with step A); C. treating the yeast suspension in a nanocavitator (70, 70?, 70??, 70??), and D. separating (80) beta glucan as solid or a solid suspension containing beta glucan from the yeast suspension.

Abstract: A process for forming an epoxidized rubber including dissolving a rubber in a solvent and epoxidizing the rubber in the presence of an epoxidation reagent. The solvent is selected such that the rubber is soluble therein but the epoxidized rubber precipitates.

Abstract: The activity of an in situ prepared Ziegler Natta catalyst in a solution polymerization may be tuned on a continuous basis by monitoring the catalyst activity (conversions) and on a frequent periodic basis incrementally adjusting the alkyl halide in the catalyst to optimize the activity.

Abstract: The present disclosure provides a method for preparing a catalyst system comprising contacting in an aliphatic solvent at a temperature of from less than 0° C. to ?60° C. at least one support material having absorbed water and at least one hydrocarbyl aluminum compound to form a supported alumoxane (catalyst precursor) and contacting the supported alumoxane with at least one catalyst compound having a Group 3 through Group 12 metal atom or lanthanide metal atom. The supported alumoxane may be heated prior to contact with the catalyst compound.

Abstract: The instant invention relates to the use of titanium-based oxopolymers for preparing suitable catalysts for reactions of olefin polymerization and/or olefin and alpha-olefin copolymerization. The instant invention further discloses the synthesis of catalyst formulated from titanium-based oxopolymers, as well as its use for olefin polymerization and/or copolymerization reactions.

Abstract: The present disclosure provides methods for preparing a catalyst system comprising contacting in an aliphatic solvent at least one support material, at least one hydrocarbyl aluminum compound and at least one non-hydrolytic active oxygen-containing compound to form a supported alumoxane (catalyst precursor) and contacting the supported alumoxane with at least one catalyst compound having a Group 3 through Group 12 metal atom or lanthanide metal atom. The supported alumoxane may be heated prior to contact with the catalyst compound.

Abstract: The invention relates to fluoropolymer filament for use in 3-D printing, and 3-D printed fluoropolymer articles having low warpage, excellent chemical resistance, excellent water resistance, flame resistance, and good mechanical integrity. Additionally, the articles of the invention have good shelf life without the need for special packaging. In particular, the invention relates to filament, 3-D printed polyvinylidene fluoride (PVDF) articles, and in particular material extrusion 3-D printing. The articles may be formed from PVDF homopolymers, copolymers, such as KYNAR® resins from Arkema, as well as polymer blends with appropriately defined low shear melt viscosity. The PVDF may optionally be a filled PVDF formulation. The physical properties of the 3-D printed articles can be maximized and warpage minimized by optimizing processing parameters.

Abstract: Provided is a polyethylene material and application thereof. A density distribution of the polyethylene material is in a range of 0.880 g/cm3-0.960 g/cm3. An amount of a fraction at a temperature of 40° C. obtained by conducting temperature rising elution fractionation on the polyethylene material is in a range of 9.0 wt %-40.0 wt %, preferably in a range of 10.0 wt %-25.0 wt %, more preferably in a range of 9.9 wt %-20.0 wt %. A melting temperature of the polyethylene material is 110° C.-135° C., preferably 116° C.-130° C. The polyethylene material provided by the present application has distinctly improved amount of medium/low-molecular-weight fractions and high-degree-branching fractions, as well as relatively high-molecular-weight fractions which are highly branched. The polyethylene material thus has a relative high melting temperature.

Abstract: The present disclosure provides a supported catalyst system and process for use thereof. In particular, the catalyst system includes four different catalysts, a support material and an activator. The catalyst system may be used for preparing polyolefins, such as polyethylene.

Abstract: The present invention relates to a high-density ethylene-based polymer comprising: an ethylene homopolymer; or a copolymer of ethylene and at least one comonomer selected from the group consisting of ?-olefins, cyclic olefins and linear, branched and cyclic dienes. According to the present invention, the high-density ethylene-based polymer has a wide molecular weight distribution and excellent comonomer distribution characteristics, has excellent melt flowability due to a long chain branched structure, and has excellent mechanical characteristics since the comonomer distribution is concentrated in a high-molecular-weight body. The high-density ethylene polymer of the present invention has excellent molding processability during processing such as extrusion, compression, injection and rotational molding by having excellent mechanical characteristics and melt flowability.

Abstract: A method of producing a copolymer of the present invention is a method of producing a specific copolymer and includes: a pure water production step of producing pure water having an electric conductivity of from 0.1 ?S/cm to 100 ?S/cm; a pure water transfer step of introducing the pure water into a reaction kettle for producing the copolymer through a transfer pipe using, as a material therefor, a resin or a substance forming a passive state in water; and a polymerization step of performing polymerization of the monomer (a), the monomer (b), and the monomer (c) in the reaction kettle, the pure water transfer step including setting the electric conductivity of the pure water at a site where the pure water is introduced from the transfer pipe toward the reaction kettle within a range of from 0.1 ?S/cm to 100 ?S/cm.

Abstract: The present invention provides a polymer composition comprising, in copolymerized form, one or more addition polymerizable arylcyclobutene monomers A having an alkyl, aryl, alkoxy, aryloxy, thioalkyl or thioaryl cyclobutene ring substituent, one or more aromatic addition polymerizable second monomers and one or more addition polymerizable monomer chosen from one or more nitrogen heterocycle containing third monomers, one or more addition polymerizable fourth monomer, such as n-butyl acrylate, or one or more of both monomers. The polymer compositions find use in making thin films or coatings having improved flexibility. Methods for making the polymer compositions are also provided.

Abstract: The present invention provides a low temperature polymerizing and curing polymer composition comprising, in copolymerized form, one or more addition polymerizable arylcyclobutene monomers A having as a cyclobutene ring substituent one or more groups chosen from alkyl; heteroatom containing alkyl; aryl; heteroatom containing aryl; or heteroatom containing aryloxy, one or more aromatic addition polymerizable second monomers, and one or more other addition polymerizable monomers chosen from an addition polymerizable nitrogen heterocycle containing third monomer, an addition polymerizable fourth monomer, or, preferably, both of the one or more third monomers and the one or more fourth monomers. The polymer compositions find use in making films or coatings for use in electronics applications.

Abstract: The present invention relates to a latex composition for dip-molding and a molded article produced therefrom. More specifically, the composition not only has gentle syneresis, and excellent tensile strength, elongation and modulus, and excellent durability against perspiration, but also is capable of preparing the dip-molded articles having excellent wearing sensation.

Abstract: According to the present invention, provided is a polymerizable composition for an optical material including: at least one amine compound (A) selected from a compound (a1) represented by Formula (1) and a compound (a2) represented by Formula (2); an iso(thio)cyanate compound (B) which contains two or more iso(thio) cyanate groups; and a polythiol compound (C) which contains a dithiol compound (c1) containing two mercapto groups and a polythiol compound (c2) containing three or more mercapto groups.

Abstract: One purpose of the present invention is to provide a liquid-crystal compound which exhibits liquid crystallinity at low temperatures. Another purpose of the present invention is to provide a thermally responsive material which exhibits liquid crystallinity and rubber elasticity at low temperatures (around room temperature) ever, though a large amount of a liquid-crystal compound is contained therein, and a method for producing this thermally responsive material. A liquid-crystal compound according to the present invention is obtained by adding an alkylene oxide and/or styrene oxide to a mesogenic group-containing compound that has an active hydrogen group.

Abstract: In various embodiments, the present invention is directed to new low cost initiator compositions for use with the production of well-defined telechelic PIBs (by LC+P of isobutylene). In various other embodiments, the present invention is directed to methods for using these novel compositions as initiators for isobutylene (IB) and other cationically polymerizable monomers, such as styrene and its derivatives. In still other embodiments, the present invention is directed to structurally new, allyl (and chlorine) telechelic PIBs formed from these new initiator compositions and their derivatives (in particular, hydroxyl telechelic PIB and amine telechelic PIB). In yet other embodiments, the present invention is directed to structurally new polyurethanes, polyureas, and polyurethane ureas made using telechelic PIBs formed from these new initiator compositions.

Abstract: The present invention relates to a melt processable thermoplastic polyurethane-urea composition formed by a continuous bulk process without the presence of solvent using a polyol component, an isocyanate component, and chain extender component comprising a hindered aromatic diamine.

Abstract: Polymerizable composition comprising a) at least one cyclic amide, b) from 1.6 to 5.0% by weight, preferably from 1.8 to 3.5% by weight, of at least one blocked polyisocyanate, and c) from 0.8 to 2.0% by weight of at least one catalyst for the polymerization of the cyclic amide and d) from 0.1 to 0.8% by weight, preferably from 0.3 to 0.6% by weight, of the dye C.I. Solvent Black 7, where the weight data for components a) to d) are based on the entirety of components a) to d), and the entirety of components a) to d) provides 100%.

Abstract: A packaging material is provided. The packaging material includes (a) epoxy silsesquioxane, (b) epoxy resin, and (c) siloxane-imide-containing benzoxazine compound. (a) Epoxy silsesquioxane and (b) epoxy resin have a weight ratio of 0.3:1 to 10:1. The total weight of (a) epoxy silsesquioxane and (b) epoxy resin and the weight of (c) siloxane-imide-containing benzoxazine compound have a ratio of 100:20 to 100:150.

Abstract: Curable epoxy resin compositions suitable for liquid resin infusion processes. In one embodiment, the resin composition contains (a) at least two polyepoxides, one of which is triglycidyl ether of tris(hydroxyphenyl)methane, (b) an aromatic amine curing agent, and (c) core-shell rubber particles. In another embodiment, the resin composition (a) at least two polyepoxides, one of which is diglycidyl ether of bis(hydroxyphenyl)fluorene, (b) an aromatic amine curing agent, and (c) core-shell rubber particles.

Abstract: Kits, recyclable covalently crosslinked polymer networks and composites, and related methods of making and recycling are described.

Abstract: The present invention relates to a process for producing cycloalkenamer-containing compositions and to such cycloalkenamer-containing compositions. The invention further relates to the use of these cycloalkenamer-containing compositions in the field of packaging materials, especially for food and drink.

Abstract: Methods for fabricating three-dimensional objects by 3D-inkjet printing technology are provided. The methods utilize curable materials that polymerize via ring-opening metathesis polymerization (ROMP) for fabricating the object, in combination with acid-activatable pre-catalyst and an acid generator activator. Kits containing modeling material formulations usable in the methods are also provided.